TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02851212
Drug: Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC]
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will receive 1 XR FDC tablet containing canagliflozin 150 mg and metformin 1000 mg orally under fed (Treatment B)or fasted condition (Treatment D) in a given treatment period as per treatment sequence.
Study: NCT02851212
Drug: Canagliflozin
Normalized name: Canagliflozin
DrugBank: Canagliflozin (DB08907)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive canagliflozin 150 mg (50 mg+100 mg oral tablets) under fed (part of Treatment A) or fasted condition (part of Treatment C) in a given treatment period as per treatment sequence.
Study: NCT02851212
Drug: Canagliflozin
Normalized name: Canagliflozin
DrugBank: Canagliflozin (DB08907)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive canagliflozin 100 mg oral tablet under fed (part of Treatment A) or fasted condition (part of Treatment C) in a given treatment period as per treatment sequence.
Study: NCT02851212
Drug: Metformin Extended Release (XR)
Normalized name: metformin Extended Release Suspension
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will receive metformin XR 500 mg tablet orally under fed (part of Treatment A) or fasted condition (part of Treatment C) in a given treatment period as per treatment sequence.
Study: NCT04798326
Drug: MW032
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects would receive a single 120mg (1.7 mL) of MW032 through subcutaneous injection, on the first day of treatment.
Study: NCT02259686
Drug: Apelin 1mg subcutaneous
Normalized name: Apelin
DrugBank: Apelin (DB18909)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single subcutaneous injection of Apelin 1mg subcutaneous
Study: NCT02259686
Drug: Apelin 1mg intravenous
Normalized name: Apelin
DrugBank: Apelin (DB18909)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 minute intravenous bolus of Apelin 1mg intravenous
Study: NCT02259686
Drug: Apelin 5mg subcutaneous
Normalized name: Apelin
DrugBank: Apelin (DB18909)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single subcutaneous injection of Apelin 5mg subcutaneous
Study: NCT02259686
Drug: Apelin 5mg intravenous
Normalized name: Apelin
DrugBank: Apelin (DB18909)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 minute intravenous infusion of Apelin 5mg intravenous
Study: NCT02259686
Drug: Apelin 10 mg subcutaneous
Normalized name: Apelin
DrugBank: Apelin (DB18909)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 hour continuous subcutaneous infusion of Apelin 10 mg subcutaneous
Study: NCT02624128
Drug: Valproic Acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment will be administered orally starting at day -14, with 500 mg slow releasing tablet at evening. Thereafter, the dose will be increased also using 300 mg tablets until reaching 1500 mg on day -1. The titration strategy is to reach a target VPA serum level of 50-100 μg/ml.
Study: NCT02624128
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: administered intravenously at dose of 75 mg/m2 given every three weeks for 6 cycles
Study: NCT02624128
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: administered intravenously at induction dose of 400 mg/m2 followed by maintenance doses of 250 mg/m2 given weekly
Study: NCT03510078
Drug: Insulin
Normalized name: Insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin for glycemic control according to the allocation
Study: NCT03046056
Drug: Filgotinib
Normalized name: Filgotinib
DrugBank: Filgotinib (DB14845)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Tablet(s) administered orally once daily
Study: NCT03046056
Drug: Placebo to match filgotinib
DrugBank: Filgotinib (DB14845)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Tablet(s) administered orally once daily
Study: NCT01282333
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01282333
Drug: veliparib
Normalized name: veliparib
DrugBank: Veliparib (DB07232)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given orally
Study: NCT01282333
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00642954
Drug: Vorinostat
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vorinostat 300 mg or 400 mg QD via oral capsule on Days 1-7 and Days 15-21 of each 28-day cycle.
Study: NCT00642954
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide 10 mg, 15 mg, 20 mg or 25 mg QD via oral capsule on Days 1-21 of each 28-day cycle.
Study: NCT00642954
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone 40 mg QD via oral tablet on Days 1, 8, 15 and 22 of each 28-day cycle.
Study: NCT02419651
Drug: Tramadol
Normalized name: Tramadol
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Women will receive oral tramadol 100 mg 1 hour before the procedure
Study: NCT00102154
Drug: MK0928, gaboxadol / Duration of Treatment: 10 months
DrugBank: Gaboxadol (DB06554)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02578940
Drug: 18F-Fluciclovine PET CT
Normalized name: fluciclovine (18F)
DrugBank: Fluciclovine (18F) (DB13146)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Radioligand for PET CT scanning
Study: NCT01066793
Drug: Peginterferon alfa-2a [Pegasys]
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peginterferon/ribavirin treatment period as prescribed by treating physician (e.g. 24 or 48 weeks) and treatment-free follow-up period of 24 weeks.
Study: NCT01066793
Drug: Peginterferon alfa-2b [PegIntron®]
DrugBank: Peginterferon alfa-2b (DB00022)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peginterferon/ribavirin treatment period as prescribed by treating physician (e.g. 24 or 48 weeks) and treatment-free follow-up period of 24 weeks.
Study: NCT03774394
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Both CKD and Non-CKD patients will be administered a 600-mg LD of clopidogrel followed by a single 75-mg MD administered after 24 hours.
Study: NCT03774394
Drug: Clopidogrel active metabolite
Normalized name: Clopidogrel active metabolite
DrugBank: 2-(1-(1-(2-chlorophenyl)-2-methoxy-2-oxoethyl)-4-sulfanyl-3-piperidinylidene) acetic acid (DB19221)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In both CKD and Non-CKD patients, blood samples collected at baseline only (before clopidogrel LD administration) will be incubated with escalating concentrations of clopidogrel active metabolite (1, 3 and 10 μM)
Study: NCT02864316
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00298363
Drug: Tenofovir disoproxil fumarate (tenofovir DF; TDF)
Normalized name: Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300-mg tablet QD
Study: NCT00298363
Drug: Entecavir (ETV)
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5-mg or 1-mg tablet QD
Study: NCT00855699
Drug: Acamprosate
Normalized name: Acamprosate
DrugBank: Acamprosate (DB00659)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acamprosate 333mg tablets, two tablets three times a day for duration of alcohol detox.
Study: NCT00846690
Drug: TAC alternate gel
Normalized name: Alternaria alternata
DrugBank: Alternaria alternata (DB10424)
Approvals — FDA: no, EMA: no, PMDA: no
Description: use 1 pump, place topically onto site, leave for 1-3 minutes
Study: NCT01660230
Drug: 0.9% NaCl in water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02263729
Drug: Losartan
Normalized name: Losartan
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cozaar
Study: NCT01928199
Drug: Sitagliptin
Normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00755261
Drug: Avastin
Normalized name: Avastin
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Combination of Avastin and doxorubicin. If initial 90 +/- 15 minute infusion of Avastin is tolerated without fever and chills, the 2nd dose may be infused over 60 +/- 10 minutes. If well tolerated, all subsequent infusions may be delivered over 30 +/- 10 minutes.
Study: NCT05672680
Drug: 0.25% Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: received during TAP block
Study: NCT03959488
Drug: Palivizumab
Normalized name: palivizumab
DrugBank: Palivizumab (DB00110)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Approved anti-RSV monoclonal antibody
Study: NCT01026818
Drug: Tadalafil
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered by mouth for 9 months
Study: NCT01760447
Drug: Sitagliptin plus metformin
Normalized name: metformin / sitagliptin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants received 2 tablets daily, one taken with a morning meal and one taken with an evening meal, to provide a total daily dose of 100 mg of sitagliptin and 1000 mg, 1700 mg or 2000 mg of metformin. Dosage of metformin was based on each participant's daily metformin dose prior to enrollment.
Study: NCT01760447
Drug: Placebo to metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants received 2 tablets daily, one taken with a morning meal and one taken with an evening meal. Each tablet contained placebo to metformin.
Study: NCT01760447
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants received 2 tablets daily, one taken with a morning meal and one taken with an evening meal, to provide a total daily dose of 1000 mg, 1700 mg or 2000 mg of metformin. Dosage was based on each participant's daily metformin dose prior to enrollment.
Study: NCT01760447
Drug: Placebo to sitagliptin plus metformin
Normalized name: metformin / sitagliptin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants received 2 tablets daily, one taken with a morning meal and one taken with an evening meal. Each tablet contained placebo to sitagliptin plus metformin.
Study: NCT01760447
Drug: Sitagliptin plus metformin XR
Normalized name: metformin / sitagliptin Extended Release Oral Tablet
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants received 2 tablets daily, both taken together with a meal, to provide a total daily dose of 100 mg of sitagliptin and 1000 mg, 1500 mg or 2000 mg of metformin. Dosage of metformin XR was based on each participant's daily metformin dose prior to enrollment.
Study: NCT01760447
Drug: Placebo to metformin XR
Normalized name: metformin Extended Release Suspension
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants received 2 tablets daily, both taken together with a meal. Each tablet contained placebo to metformin XR.
Study: NCT01760447
Drug: Insulin
Normalized name: Insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants who met protocol-specific glycemic rescue criteria received insulin as glycemic rescue therapy; participants on background insulin had their insulin dose increased for glycemic rescue. During Weeks 20-54, for participants who were not on background insulin or rescued with insulin during Weeks 0-20 in the Sitagliptin/Metformin and Metformin arms (protocol MK-0431A-170), and during Weeks 0-54 for participants not on background insulin in the Sitagliptin/Metformin XR and Metformin XR arms (protocol MK-0431A-289), the type of insulin for glycemic rescue was specified to be insulin glargine.
Study: NCT01760447
Drug: Placebo to sitagliptin plus metformin XR
Normalized name: metformin / sitagliptin Extended Release Oral Tablet
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants received 2 tablets daily, both taken together with a meal. Each tablet contained placebo to sitagliptin plus metformin XR.
Study: NCT01760447
Drug: Metformin XR
Normalized name: metformin Extended Release Suspension
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants received 2 tablets daily, both taken together with a meal, to provide a total daily dose of 1000 mg, 1500 mg or 2000 mg of metformin XR. Dosage was based on each participant's daily metformin dose prior to enrollment.
Study: NCT04150536
Drug: Lidocaine topical system 1.8%
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00547417
Drug: tadalafil
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg tadalafil tablet taken by mouth, as needed, no more than once a day, for 12 weeks.
Study: NCT03027245
Drug: Eribulin
Normalized name: Eribulin
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00571116
Drug: Arsenic trioxide
Normalized name: Arsenic Trioxide
DrugBank: Arsenic trioxide (DB01169)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IV
Study: NCT00285376
Drug: vilazodone
Normalized name: Vilazodone
DrugBank: Vilazodone (DB06684)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: titration to 40mg tablets qd for 8 weeks
Study: NCT00575471
Drug: Rivoglitazone HCl
Normalized name: Pioglitazone Hydrochloride
DrugBank: Rivoglitazone (DB09200)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg tablets once daily for 12 weeks
Study: NCT00575471
Drug: rivoglitazone HCl
Normalized name: Pioglitazone Hydrochloride
DrugBank: Rivoglitazone (DB09200)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg tablets once daily for 12 weeks
Study: NCT00575471
Drug: rivoglitazone HCl
Normalized name: Pioglitazone Hydrochloride
DrugBank: Rivoglitazone (DB09200)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg tablets once daily for 12 weeks
Study: NCT02932605
Drug: Cannabidiol
Normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cannabidiol
Study: NCT02004314
Drug: Chloroquine
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04575584
Drug: Molnupiravir
Normalized name: Molnupiravir
DrugBank: Molnupiravir (DB15661)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Molnupiravir administered orally in capsule form every 12 hours for 5 days (10 doses total)
Study: NCT02865629
Drug: N-acetyl cysteine
Normalized name: N-Acetyl Cysteine
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine will be initiated at 600 mg PO daily for Week 1, then increased to 600 mg PO twice a day for Week 2, then increased to 600 mg PO morning and 1200 mg PO evening for Week 3, and then increased to 1200 mg PO twice a day for Week 4-8. Doses might be decreased anytime if clinically indicated. Following the study, all patients will be referred to treatment as usual. Adherence will be assessed in weekly visits in the first month and then bi-weekly in the second month. Adherence will be assessed by subject interview, pill counts during each study visit, and by legal guardian interview (if minor).
Study: NCT00568893
Drug: drotrecogin alfa (activated)
Normalized name: DROTRECOGIN ALFA (ACTIVATED)
DrugBank: Drotrecogin alfa (DB00055)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01756339
Drug: Solithromycin
Normalized name: solithromycin
DrugBank: Solithromycin (DB09308)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01756339
Drug: Moxifloxacin
Normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03739801
Drug: Liposomal Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02653898
Drug: Primaquine
Normalized name: Primaquine
DrugBank: Primaquine (DB01087)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 22.5 mg weekly for 12 weeks in the MMP arm; low dose primaquine (15mg) for transmission blocking of P. falciparum or 14 days of primaquine (15mg) in G6PD normal volunteers or 8 weeks of low dose primaquine (45mg) in G6PD-deficient volunteers for radical cure of P. vivax
Study: NCT02653898
Drug: Artesunate + Mefloquine
Normalized name: artesunate and mefloquine
DrugBank: Mefloquine (DB00358)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weight based; first line agent for P.f malaria infection diagnosed at monthly follow ups, administered on days 1-3 in subjects with malaria recurrence
Study: NCT02653898
Drug: Permethrin (Insecticide treated uniform)
Normalized name: Permethrin
DrugBank: Permethrin (DB04930)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40% Permethrin IDA kit, applied once to the uniforms for volunteers assigned to ITU arm
Study: NCT00004197
Drug: mitoxantrone hydrochloride
Normalized name: Mitoxantrone Hydrochloride
DrugBank: Mitoxantrone (DB01204)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00004197
Drug: prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00004197
Drug: vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01955577
Drug: Vitamin D3 cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04293172
Drug: Brilinta
Normalized name: Brilinta
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in the open-label Run-in period (patients aged 6 to \<24 months only) will receive ticagrelor 5 mg twice a day (body weight 6 to ≤9 kg), 10 mg twice a day (body weight \>9 to ≤12 kg) or 15 mg twice a day (body weight \>12 to ≤24 kg) for 14 days.~The double-blind IP will be based on 5 weight bands:~* 6 to ≤9 kg: ticagrelor 5 mg or matching placebo, twice a day~* \>9 to ≤12 kg: ticagrelor 10 mg or matching placebo, twice a day~* \>12 to ≤24 kg: ticagrelor 15 mg or matching placebo, twice a day~* \>24 to ≤48 kg: ticagrelor 30 mg or matching placebo, twice a day~* \>48 kg: ticagrelor 45 mg or matching placebo, twice a day
Study: NCT02527317
Drug: Lipegfilgrastim
Normalized name: Lipegfilgrastim
DrugBank: Lipegfilgrastim (DB13200)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Investigate the incidence of treatment-related neutropenia following four cycles of dose dense (every 2 week) doxorubicin cyclophosphamide (AC) with lipegfilgrastim support (8 weeks).
Study: NCT00715520
Drug: Carbidopa-Levodopa
Normalized name: Carbidopa-Levodopa
DrugBank: Carbidopa (DB00190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive one oral dose of carbidopa-levodopa 25mg one hour prior to measuring wrist extension movements.~The order in which Carbidopa-Levodopa is given will be randomized per participant.
Study: NCT00715520
Drug: Methylphenidate
Normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive one oral dose of methylphenidate 40mg 2 hours prior to measuring wrist extension movements.~The order in which Methylphenidate is given will be randomized per participant.
Study: NCT00715520
Drug: Amphetamine Sulfate
Normalized name: amphetamine sulfate
DrugBank: Amphetamine (DB00182)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive one oral dose of amphetamine sulfate 10mg 2 hours prior to measuring wrist extension movements.~The order in which Amphetamine Sulfate is given will be randomized per participant.
Study: NCT00146549
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00146549
Drug: Vinorelbine
Normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00146549
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00146549
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02711943
Drug: Levofloxacin 500
Normalized name: levofloxacin 500 MG
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral levofloxacin (Levolet®) at a dose of 500 mg once a day for 28 days
Study: NCT03208413
Drug: Thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Thalidomide with a dosage of 25 mg at bedtime daily one week (days 1-7), then 50 mg at bedtime daily for one week (days 8-14), then 75 mg at bedtime daily for one week (days 15-21), then 100 mg at bedtime daily for 12 weeks (days 22-105), in the absence of unacceptable toxicity or severe deterioration.
Study: NCT03564093
Drug: Intranasal Drug
Normalized name: NALOXONE RESCUE KIT INTRANASAL
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1µg/kg of dexmedetomidine is given 30 minutes prior to intravenous cannulation or lumbar puncture
Study: NCT03564093
Drug: Intranasal Drug
Normalized name: NALOXONE RESCUE KIT INTRANASAL
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal 4,5% saline is given as a placebo 30 minutes prior to intravenous cannulation or lumbar puncture
Study: NCT04480996
Drug: Drugs Responsible for Cognitive Side Effects
Normalized name: cured fat, pork side bacon
DrugBank: Pork (DB10561)
Approvals — FDA: no, EMA: no, PMDA: no
Description: identification of road traffic accidents associated with drugs responsible for psychomotor side effects
Study: NCT03832673
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab 200 mg IV every 3 weeks (for 3 cycles)
Study: NCT03832673
Drug: Epacadostat
Normalized name: epacadostat
DrugBank: Epacadostat (DB11717)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epacadostat 300 mg (BID) orally continuously every 28 days (for 3 cycles)
Study: NCT00496587
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 900 mg/m\^2 By Vein Over 30 Minutes on Days 1 and 15.
Study: NCT00496587
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 10 mg/kg By Vein On Days 1 and 15.
Study: NCT04848246
Drug: Bupropion
Normalized name: Bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This group received Bupropion 150 mg twice daily for 10 weeks
Study: NCT01515696
Drug: Gastrografin
Normalized name: Gastrografin
DrugBank: Diatrizoate (DB00271)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive 3ml Gastrografin + 6ml sterile water/kg as a single dose via a nasogastric tube during the first 24 hours of life.